Foley Partner Jacqueline Wright Bonilla was quoted in an article that appeared in BioWorld Insight on August 16, 2010 titled “If NIH Challenges Genzyme’s Patents, Does Anyone Care?” Wright Bonilla discusses a petition filed with the Department of Health and Human Services urging the National Institutes of Health (NIH) to exercises its march-in rights and grant an open license for the use of patents related to Genzyme Corp.’s Fabry disease drug Fabrazyme. She states that it is unlikely that the NIH would pursue an open license for Genzyme’s product because of the complexity of making biologics like Fabrazyme, adding that the agency has in fact never before exercised its march-in rights.
Related News
April 13, 2026
In the News
Increase in Demand and Firm Growth Led Foley to Large Leaps in Revenue and PEP in a 'Year When It All Came Together'
Foley & Lardner LLP saw double-digit increases and all-time highs across all financial metrics in 2025 as noted in The American Lawyer article, “Foley Grows Revenue by Nearly 14%, PEP by 27%, in a 'Year When It All Came Together'.”
April 10, 2026
In the News
Foley's Texas Media Roundtable Highlighted for Insights on Today's Energy Transformations
Foley & Lardner LLP is featured across media for the firm’s recent roundtable discussion on energy trends related to grid reliability, data centers, and capital investments.
April 10, 2026
In the News
Deanna Reitman and Glenn Reitman Highlighted Across Media for Foley Arrival
Foley & Lardner LLP partners Deanna Reitman and Glenn Reitman attracted widespread media coverage for their recent arrival to the firm’s Houston office.